GlassScriptPhysician profile
Naveen Doki
NPI 1568621779
$3,403.98
in general payments reported to CMS, 2019-2025
41 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,217 · 2020: $645 · 2021: $80.14 · 2022: $87.05 · 2023: $140 · 2024: $121 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.30 |
| Education | $113.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $652.71 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $286.15 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $243.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $217.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $136.12 | 2019-2025 | |
| Seagen INC. | $132.04 | 2019-2020 | |
| Eisai INC. | $126.09 | 2019 | |
| Daiichi Sankyo INC. | $125.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.97 | 2019-2020 | |
| Mylan Institutional INC. | $115.72 | 2019-2020 | |
| Pfizer INC. | $106.51 | 2019-2020 | |
| Amgen INC. | $99.05 | 2019-2020 | |
| Genentech USA, INC. | $91.97 | 2019-2020 | |
| Genzyme Corporation | $75.14 | 2019-2020 | |
| Foundation Medicine, INC. | $71.48 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $56.55 | 2019 | |
| Heron Therapeutics, INC. | $55.55 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $53.11 | 2019-2020 | |
| Lilly USA, LLC | $48.27 | 2019-2020 | |
| Puma Biotechnology, INC. | $45.56 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $41.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.07 | 2019-2020 | |
| Roche Diagnostics Corporation | $33.00 | 2019 | |
| Sobi, INC | $32.57 | 2024 | |
| Abbvie INC. | $30.59 | 2024 | |
| Glaxosmithkline, LLC. | $29.22 | 2020 | |
| Beigene USA, INC. | $27.14 | 2022 | |
| Emd Serono, INC. | $23.72 | 2020 | |
| Tesaro, INC. | $23.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.75 | 2019 | |
| Abbott Laboratories | $22.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.99 | 2019 | |
| Clovis Oncology, INC. | $18.75 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.01 | 2020 | |
| Octapharma USA, INC. | $17.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.73 | 2019 | |
| Secura Bio, INC. | $16.57 | 2019 | |
| Incyte Corporation | $15.69 | 2020 | |
| Endo Pharmaceuticals INC. | $15.19 | 2019 | |
| Eusa Pharma (US) LLC | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Doki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.